Fondaparinux in heparin-induced thrombocytopenia

Acta Cardiol. 2013 Oct;68(5):517-20. doi: 10.1080/ac.68.5.2994477.

Abstract

Heparin-induced thrombocytopenia is a potentiallylife-threatening complication of heparin or low-molecular-weight heparin administration. We describe the case of a patient with heparin-induced thrombocytopenia complicated by pulmonary embolism, successfully treated with fondaparinux, a factor Xa inhibitor. We also review the literature regarding the use of this anticoagulant in heparin-induced thrombocytopenia complicated by thrombosis. Few treatment options are available in Belgium, and there is little evidence regarding newer anticoagulants.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Factor X
  • Female
  • Fondaparinux
  • Heparin, Low-Molecular-Weight / adverse effects*
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Polysaccharides / therapeutic use*
  • Pulmonary Embolism / drug therapy
  • Thrombocytopenia / chemically induced*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Polysaccharides
  • Factor X
  • Fondaparinux